Defence Therapeutics Market Capitalization vs. Cash Per Share
| DTCFF Stock | USD 0.41 0.00 0.00% |
For Defence Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Defence Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Defence Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Defence Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Defence Therapeutics over time as well as its relative position and ranking within its peers.
Defence |
Defence Therapeutics Cash Per Share vs. Market Capitalization Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Defence Therapeutics's current stock value. Our valuation model uses many indicators to compare Defence Therapeutics value to that of its competitors to determine the firm's financial worth. Defence Therapeutics is one of the top stocks in market capitalization category among its peers. It also is one of the top stocks in cash per share category among its peers . The ratio of Market Capitalization to Cash Per Share for Defence Therapeutics is about 14,344,846,400 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Defence Therapeutics' earnings, one of the primary drivers of an investment's value.Defence Market Capitalization vs. Competition
Defence Therapeutics is one of the top stocks in market capitalization category among its peers. Market capitalization of Biotechnology industry is currently estimated at about 264.27 Million. Defence Therapeutics totals roughly 143.45 Million in market capitalization claiming about 54% of stocks in Biotechnology industry.
Defence Cash Per Share vs. Market Capitalization
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Defence Therapeutics |
| = | 143.45 M |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Defence Therapeutics |
| = | 0.01 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Defence Cash Per Share Comparison
Defence Therapeutics is currently under evaluation in cash per share category among its peers.
Defence Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Defence Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Defence Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Defence Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Defence Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biologicalbiosimilar therapeutic drugs for cancer and infectious diseases. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada. Defence Therapeutics is traded on OTC Exchange in the United States.
Defence Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Defence Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Defence Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Defence Therapeutics' important profitability drivers and their relationship over time.
Use Defence Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Defence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Defence Therapeutics will appreciate offsetting losses from the drop in the long position's value.Defence Therapeutics Pair Trading
Defence Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Defence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Defence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Defence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Defence Therapeutics to buy it.
The correlation of Defence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Defence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Defence Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Defence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Defence Therapeutics position
In addition to having Defence Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Size And Style ETFs Thematic Idea Now
Size And Style ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Size And Style ETFs theme has 1094 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Size And Style ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Defence OTC Stock
To fully project Defence Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Defence Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Defence Therapeutics' income statement, its balance sheet, and the statement of cash flows.